We are live on ! Find out more

Dyadic International

DYAI

Market cap $16.6M

0.4150 USD

-0.0087

2.05%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

0.4150

0.0000

0%

1 day

-2.05%

5 days

-14.26%

1 month

-45.69%

3 months

-46.93%

6 months

-46.79%

Year to date

-55.85%

1 year

-57.72%

5 years

-92.33%

10 years

-87.79%

About: Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.

Employees: 5

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript

Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript

Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript

Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement

JUPITER, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ: DYAI) (the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food and nutrition, bio-industrial and biopharmaceutical markets, today announced definitive agreements with an institutional investor for the purchase and sale of shares of Common Stock in a registered direct offering with a concurrent private placement of warrants to the same investor.

Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement

Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript

Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript

Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript

Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas

JUPITER, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today reported its financial results for the second quarter ended June 30, 2026, highlighting significant progress in product commercialization, strategic partnerships, and C1 biomanufacturing platform expansion.

Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas

Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement

JUPITER, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food & nutrition, bioindustrial and biopharmaceutical markets, today announced the expansion of its commercial non-animal dairy pipeline through a new development and commercial license agreement with a European biotechnology company for additional precision-fermented dairy proteins.

Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement

Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026

JUPITER, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the quarter ended Jun 30, 2026 and host a corporate update conference call on Wednesday, August 12, 2026.

Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026

Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days

JUPITER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, today announced that, within approximately 15 days of receiving the plasmids, it developed stable pools of C1 cell lines and manufactured and initially purified two Scripps-designed Bundibugyo ebolavirus recombinant protein antigens.

Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days

Dyadic Announces Continued Listing on the Nasdaq Capital Market

JUPITER, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food and nutrition, bio-industrial and biopharmaceutical markets, today announced that Nasdaq has confirmed that the Company has regained compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b).

Dyadic Announces Continued Listing on the Nasdaq Capital Market

Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program

JUPITER, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food, nutrition, bio-industrial and biopharmaceutical markets, today announced the expansion of its bio-industrial pipeline with a new proprietary industrial enzyme program focused on advanced cellulose processing.

Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program

Global Collaborations Continue to Validate Dyadic's C1 Platform and Expands Commercial Potential

Global Collaborations Continue to Validate Dyadic's C1 Platform and Expand Commercial Opportunity Dyadic's Ebola preparedness work highlights C1's potentia

Global Collaborations Continue to Validate Dyadic's C1 Platform and Expands Commercial Potential

See News Rankings

Price charts implemented using Lightweight Charts™